AVANIR PHARMACEUTICALS INC (AVNR)

Overview Price 3.03 Price Change Today -$0.07 (-2.26%) P&P rating Zacks Rank 3 - HOLD Open Price $3.13 Previous Close $3.10 Daily Range $3.01 - $3.18 52-Week Range $1.77 - $4.80 Volume 946,647 AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. AVANIR has an ongoing development program with Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Other Resources for AVNR Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary No Commentary Found for This Ticker. AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. AVANIR has an ongoing development program with Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.   Brokerage Analyst Recommendations 4 Brokerage Firms Covering AVNR   Strong Buy 3 Buy 0 Hold 1 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1.5   AVNR Ratings: BUY  SELL  HOLD AVNR Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 40 Buy 0 Sell   Top Buy Analysis BUY: AVNR Company: AVANIR PHARMACEUTICALS Points: 0.30 Start Price: $2.66 Start Date: 04/01/2010 11:51 PM hdget1 P&P Score: 98.67 Recs: should progress Comments: 0 | Comment More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
ThisColoradoKid	99.69	04/22/10	Next Wave	0

Commentary

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $4.27 Points: -41.18 Created: 11/22/2010 product approved. offering was above 4.50 Comments: 0 | Comment poconobear Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $4.45 Points: -44.19 Created: 11/18/2010 high up potential Comments: 0 | Comment Baggenstos Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $2.66 Points: +0.30 Created: 04/01/2010 should progress Comments: 0 | Comment hdget1 Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $1.91 Points: +39.59 Created: 12/23/2009 My target price is set to $ 5.5. It should be there by March 2010. Comments: 0 | Comment Isty Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $12.41 Points: -67.42 Created: 01/01/2008 Comments: 0 | Comment Hurricane Trader Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $3.07 Points: +7.60 Created: 01/01/2008 Comments: 0 | Comment vandal Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $2.29 Points: +41.55 Created: 01/01/2008 Comments: 0 | Comment NIANZHAN Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $14.50 Points: -70.97 Created: 01/01/2008 Comments: 0 | Comment tdrzata1 Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $4.28 Points: -20.58 Created: 01/01/2008 Comments: 0 | Comment abengtrin Recs:

BUY: AVANIR PHARMACEUTICALS (AVNR) Start Price: $14.53 Points: -71.02 Created: 01/01/2008 Comments: 0 | Comment madmax2crazy Recs:

Pages: [ 1 ]  2   3   4  >>

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
poconobear	95.08	BUY	One to Three Years	11/22/2010	$4.27	$3.06 (-1.61%)	-28.34%	+12.84%	-41.18	view close
Baggenstos	2.10	BUY	One to Three Months	11/18/2010	$4.45	$3.06 (-1.61%)	-31.24%	+12.95%	-44.19	view close
hdget1	98.67	BUY	Six Months to a Year	04/01/2010	$2.66	$3.06 (-1.61%)	+15.04%	+14.73%	+0.30	view close
Isty		BUY	One to Three Months	12/23/2009	$1.91	$3.06 (-1.61%)	+60.21%	+20.62%	+39.59	view close
Hurricane Trader		BUY	Six Months to a Year	01/01/2008	$12.41	$3.06 (-1.61%)	-75.34%	-7.92%	-67.42
vandal	41.25	BUY	Six Months to a Year	01/01/2008	$3.07	$3.06 (-1.61%)	-0.33%	-7.92%	+7.60
NIANZHAN	57.55	BUY	Six Months to a Year	01/01/2008	$2.29	$3.06 (-1.61%)	+33.62%	-7.92%	+41.55
tdrzata1	57.55	BUY	Six Months to a Year	01/01/2008	$14.50	$3.06 (-1.61%)	-78.90%	-7.92%	-70.97
abengtrin	53.45	BUY	Six Months to a Year	01/01/2008	$4.28	$3.06 (-1.61%)	-28.50%	-7.92%	-20.58
madmax2crazy		BUY	Six Months to a Year	01/01/2008	$14.53	$3.06 (-1.61%)	-78.94%	-7.92%	-71.02

Pages: [ 1 ]  2   3   4  >>